Sangamo Biosciences (SGMO) Reports Q2 Loss of $0.17/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil surge keeps S&P 500, Nasdaq in check before earnings; Salesforce lifts Dow
- Oil prices rise as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts SGMO Hot Sheet
Price: $0.18 --0%
Financial Fact:
Collaboration agreements: 2.73M
Today's EPS Names:
SMXT, NRIX, VFS, More
Financial Fact:
Collaboration agreements: 2.73M
Today's EPS Names:
SMXT, NRIX, VFS, More
Join SI Premium – FREE
Sangamo Biosciences (NASDAQ: SGMO) reported Q2 EPS of ($0.17), versus ($0.38) reported last year. Revenue for the quarter came in at $8.3 million, versus $3.7 million reported last year.
GUIDANCE:
Sangamo Biosciences sees FY2017 revenue of $30-40 million, versus the consensus of $31.2 million.
For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Can broadening earnings growth sustain the equity upcycle? JPM weighs in
- Artisan Partners Asset Management (APAM) PT Lowered at TD Cowen After 'Another Attrition-Driven Miss'
- T. Rowe Price reports $1.86 trillion in AUM for September 2026
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
